MarketCapExport financials
Sutro Biopharma (STRO)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Sutro Biopharma Balance Sheet 2025-2011 | STRO
Brief overview of Sutro Biopharma's assets and capital
This overview follows the five latest available annual observations between 2021 and 2025.
Across five reporting periods, assets decreased -49.1%, from $341.4 million to $173.8 million, producing a negative trend.
Liabilities grew faster than assets: +244.7% versus -49.1%. A substantial part of expansion was externally funded.
Shareholders' capital is negative, making the balance sheet dependent on consistent debt servicing capacity.
The period ended with net cash: net debt stood at -$42.5 million. This supports financial flexibility.
Cash represents 33.4% of assets versus 8.9% initially, showing how the immediate liquidity reserve changed.
The accumulated result is -$978 million and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.
Overall assessment
Sutro Biopharma's financial structure calls for caution. Stronger equity, lower debt or restored liquidity would be needed to improve it.
Annual Balance Sheet Sutro Biopharma
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-42.5 M | -167 M | - | -38.9 M | -13.6 M | -182 M | 3.92 M | -111 M | -7.39 M | -11.6 M | - | - | - | - | - |
Long Term Debt |
7.89 M | 15.7 M | - | 3.77 M | 15.7 M | 24.5 M | 8.88 M | 10 M | - | - | - | - | - | - | - |
Long Term Debt Current |
7.78 M | 7.48 M | 6.42 M | 4.58 M | 1.04 M | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | 55.2 M | 118 M | 110 M | - | - | - | - | - |
Total Current Liabilities |
75.1 M | 132 M | 93.7 M | 66.5 M | 41.7 M | 29.6 M | 33 M | 36.4 M | - | - | - | - | - | - | - |
Total Liabilities |
306 M | 343 M | 321 M | 190 M | 88.8 M | 62.1 M | 58.6 M | 91.6 M | 150 M | 160 M | - | - | - | - | - |
Deferred Revenue |
10.6 M | 69.8 M | 20.7 M | 16.8 M | 5.5 M | 14.6 M | 19.5 M | 21.6 M | 10.7 M | 43.6 M | - | - | - | - | - |
Retained Earnings |
-978 M | -787 M | -559 M | -453 M | -333 M | -228 M | -196 M | -150 M | -115 M | -95.3 M | - | - | - | - | - |
Total Assets |
174 M | 387 M | 471 M | 407 M | 341 M | 394 M | 156 M | 223 M | 40.8 M | 69.3 M | - | - | - | - | - |
Cash and Cash Equivalents |
58.1 M | 190 M | 69.3 M | 47.3 M | 30.4 M | 206 M | 4.96 M | 125 M | 22 M | - | - | - | - | - | - |
Book Value |
-132 M | 44.6 M | 150 M | 217 M | 253 M | 332 M | 97.8 M | 132 M | -109 M | -90.9 M | - | - | - | - | - |
Total Shareholders Equity |
-132 M | 44.6 M | 150 M | 217 M | 253 M | 332 M | 97.8 M | 132 M | -109 M | -90.9 M | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Balance Sheet Sutro Biopharma
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
7.89 M | 6.03 M | 15.7 M | 9.7 M | 11.5 M | 13.6 M | 15.7 M | 17.7 M | 19.6 M | 21.4 M | 23.2 M | 24.9 M | 26.5 M | 28.1 M | 3.77 M | 6.78 M | 9.78 M | 12.8 M | 15.7 M | 18.7 M | 21.7 M | 24.7 M | 24.5 M | 24.5 M | 24.5 M | 24.5 M | 8.88 M | 8.88 M | 8.88 M | 8.88 M | 10 M | 10 M | 10 M | 10 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
306 M | 309 M | 343 M | 297 M | 294 M | 347 M | 343 M | 341 M | 337 M | 305 M | 321 M | 319 M | 310 M | 173 M | 190 M | 171 M | 177 M | 83.3 M | 88.8 M | 87.9 M | 52.3 M | 51.2 M | 62.1 M | 62.1 M | 62.1 M | 62.1 M | 58.6 M | 58.6 M | 58.6 M | 58.6 M | 91.6 M | 91.6 M | 91.6 M | 91.6 M | 47.3 M | 47.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
10.6 M | 9.4 M | 69.8 M | 8.98 M | 12 M | 69 M | 69.8 M | 72.6 M | 74 M | 20.5 M | 20.7 M | 24 M | 18 M | 17.2 M | 16.8 M | 15.9 M | 6.49 M | 6.28 M | 5.5 M | 7.8 M | 8.13 M | 12.1 M | 14.6 M | 14.6 M | 14.6 M | 14.6 M | 19.5 M | 19.5 M | 19.5 M | 19.5 M | 21.6 M | 24.2 M | 21.6 M | 21.6 M | 10.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-978 M | -1.02 B | -787 M | -931 M | -874 M | -863 M | -787 M | -714 M | -666 M | -618 M | -559 M | -590 M | -541 M | -503 M | -453 M | -418 M | -399 M | -373 M | -333 M | -295 M | -264 M | -258 M | -228 M | -228 M | -228 M | -228 M | -196 M | -196 M | -196 M | -196 M | -150 M | -150 M | -150 M | -150 M | -115 M | -115 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
174 M | 242 M | 387 M | 210 M | 262 M | 321 M | 387 M | 452 M | 489 M | 403 M | 471 M | 432 M | 465 M | 358 M | 407 M | 401 M | 386 M | 304 M | 341 M | 371 M | 360 M | 359 M | 394 M | 394 M | 394 M | 394 M | 156 M | 156 M | 156 M | 156 M | 223 M | 223 M | 223 M | 223 M | 40.8 M | 40.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
64.9 M | 73.7 M | 191 M | 65.9 M | 64 M | 106 M | 190 M | 175 M | 90.8 M | 65.2 M | 69.3 M | 81.8 M | 235 M | 62.5 M | 47.3 M | 96.8 M | 79.1 M | 28.9 M | 30.4 M | 30.7 M | 56.4 M | 55.8 M | 206 M | 206 M | 206 M | 206 M | 4.96 M | 4.96 M | 4.96 M | 4.96 M | 125 M | 125 M | 125 M | 125 M | 22 M | 22 M | - | - | 11.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
-132 M | -66.9 M | 44.6 M | -87.3 M | -32.1 M | -25.8 M | 44.6 M | 111 M | 152 M | 98 M | 150 M | 112 M | 155 M | 185 M | 217 M | 230 M | 209 M | 220 M | 253 M | 284 M | 308 M | 307 M | 332 M | 332 M | 332 M | 332 M | 97.8 M | 97.8 M | 97.8 M | 97.8 M | 132 M | 132 M | 132 M | 132 M | -6.5 M | -6.5 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
44.6 M | -66.9 M | 150 M | -87.3 M | -32.1 M | -25.8 M | 44.6 M | 111 M | 152 M | 98 M | 150 M | 112 M | 155 M | 185 M | 217 M | 230 M | 209 M | 220 M | 253 M | 284 M | 308 M | 307 M | 332 M | 332 M | 332 M | 332 M | 97.8 M | 97.8 M | 97.8 M | 97.8 M | 132 M | 132 M | 132 M | 132 M | -109 M | -109 M | - | - | -90.9 M | - | - | - | -93.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Balance Sheet is a fundamental financial report of Sutro Biopharma, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Canada
USA
Russia
Niderland
France
Israel
Australia
Danmark
